PYC Therapeutics Highlights Progress in Its Transformation to a U.S. Clinical-Stage Company and 2021 Corporate Objectives

Share this article
Share this article
PERTH, Australia and NEW YORK, Feb. 22, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company developing a new generation of precision RNA therapeutics to change the lives of patients with inherited diseases, today announced updates to its programs and outlined its 2021-2022 corporate objectives. PYC is initially targeting inherited ocular diseases, for which it has three preclinical candidates in development.
"This year we are focused on transforming PYC Therapeutics into a U.S.-based, clinical-stage biotechnology company, including making significant advances in moving our three preclinical inherited ocular disease programs toward the clinic and leveraging our RNA platform to create new development candidates in both ocular and neurodegenerative diseases," said Sahm Nasseri, U.S. Chief Executive Officer of PYC Therapeutics. "We have previously highlighted the importance of building out PYC in the U.S. and I am pleased with our progress and external engagements we have been able to have over the last few months. These engagements with banks, potential future investors as well as potential partners have validated the importance and relevance of PYC's technology as well as our choice in initial drug development programs. RNA therapeutics and ophthalmology remain top areas of interest in the very active US biotech capital markets. On this foundation, I believe we are very well positioned to deliver on the promise of our science to advance RNA medicines that have the potential to change the lives of patients with inherited diseases."

Related Keywords

Australia , Perth , Western Australia , Australian , Kaggen Ausma , Deborah Elson Matthew Deyoung , Sahm Nasseri , Leo Vartorella , Indianj Ophthalmol , Linkedin , Us Development Capabilities , Twitter , Drug Administration , Us Management Team , Program Updates , Executive Officer , Sue Fletcher , Chief Scientific , Chief Business Officer , Chief Development Officer , Chief Financial Officer , West Coast , Cash Position , Ocular Diseases , Investigational New Drug , Nervous System , Cell Penetrating Peptides , Pyc Therapeutics , ஆஸ்திரேலியா , பெர்த் , மேற்கு ஆஸ்திரேலியா , ஆஸ்திரேலிய , டெபோரா எல்சன் மேத்யூ டியூன் , சென்டர் , ட்விட்டர் , எங்களுக்கு மேலாண்மை அணி , ப்ரோக்ர்யாம் புதுப்பிப்புகள் , நிர்வாகி அதிகாரி , வழக்கு பிளெட்சர் , தலைமை அறிவியல் , தலைமை வணிக அதிகாரி , தலைமை வளர்ச்சி அதிகாரி , தலைமை நிதி அதிகாரி , மேற்கு கடற்கரை , பணம் பொஸிஶந் , கண் நோய்கள் , பதட்டமாக அமைப்பு , பய்க் சிகிச்சை ,